AYTU BioPharma
AYTU
31 hedge funds and large institutions have $2.49M invested in AYTU BioPharma in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
7% more funds holding
Funds holding: 29 → 31 (+2)
0.17% less ownership
Funds ownership: 30.58% → 30.42% (-0.17%)
22% less capital invested
Capital invested by funds: $3.19M → $2.49M (-$703K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$81.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$28.3K |
| 3 |
JIP
Jaffetilchin Investment Partners
Tampa,
Florida
|
+$25.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$134K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$19.9K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18.2K |
| 4 |
Millennium Management
New York
|
-$17.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.8K |
AYTU Hedge Fund Activity: Q1 2025 in Review
31 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2025, worth a combined $2.49M — down 22% from $3.19M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AYTU positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $81.7K. The largest seller was Armistice Capital, cutting an estimated $134K.
- 31 institutional investors held AYTU BioPharma (AYTU) as of Q1 2025, up from 29 in Q4 2024.
- Funds reported $2.49M of AYTU BioPharma stock for Q1 2025, down 22% quarter-over-quarter.
- 7 funds opened new AYTU BioPharma positions in Q1 2025 and 5 closed out, a net change of +2 holders.
- The largest AYTU BioPharma buyer in Q1 2025 was Stonepine Capital Management, an estimated $81.7K added.
- The largest AYTU BioPharma seller in Q1 2025 was Armistice Capital, an estimated $134K sold.
Based on aggregated 13F filings for Q1 2025.